Talking Ketamine Podcast

For the estimated seven to ten percent of bereaved adults struggling with Prolonged Grief Disorder (PGD), mourning isn’t a slow march forward; it is a state of total paralysis. While typical grief allows the internal clock to keep ticking as the world spins, PGD jams the gears of recovery, trapping individuals in a closed loop of loss-oriented rumination and profound identity disruption. Standard psychiatric treatments like SSRIs frequently fail because PGD is not merely depression, and specialized, multi-session psychotherapies remain difficult for most people to access.This episode dives into a retrospective analysis of 503 adults who underwent Mindbloom's guided, at-home telehealth ketamine therapy. By acting as an NMDA receptor antagonist, ketamine decreases functional connectivity within the hyperactive default mode network (DMN)—the brain's self-referencing storytelling engine that holds onto stubborn expectations, or "high-level neural priors." Using the analogy of deeply rutted dirt roads, the constant agonizing loop of grief digs tracks so deep that the mind's tires cannot steer out of them. Ketamine essentially smooths out the dirt, filling these ruts and providing the cognitive flexibility needed for the tires to find traction. This biological window aligns with the dual process model of bereavement, allowing patients to shift from paralyzing loss to active life restoration, and ultimately reprogram their internal GPS.The clinical findings are striking: among the 121 participants who completed the six-session protocol, grief scores declined consistently, leading to a 31% average reduction in symptoms and a 76% clinical response rate. Crucially, the single largest improvement—standing at nearly 36%—occurred not in general sadness, but in identity and role confusion. While the study faces limitations like high attrition (completer bias) and the lack of a placebo control, worst-case sensitivity analysis still confirms a robust diagnostic remission rate of 18-19%. These results suggest that healing from profound loss is not a passive waiting game, but an active process of rebuilding who we are.Reference:Carter, D., Reardon, I., Swain, J., & Vando, L. (2026). Prolonged grief symptom outcomes during at-home ketamine-assisted therapy: A real-world retrospective analysis of 503 adults. Research Square. https://doi.org/10.21203/rs.3.rs-9839240/v1

For many couples, traditional talk therapy can feel like an endless loop, failing to break through entrenched patterns of distress. The stark reality? Up to a third of couples find conventional therapy ineffective, often relapsing into old arguments because logic crumbles when the nervous system is trapped in a defensive state. When our amygdala, the brain's fear processing center, perceives a partner as a threat, our survival instincts take over, shutting down the very connection we crave.Enter ketamine-assisted psychotherapy (KAP) in the relational space—a "benevolent disruptor" that biochemically dampens the amygdala, reducing fear and softening the sharp edges of human interaction. This episode unpacks a groundbreaking qualitative study profiling nine therapists who are integrating ketamine into their work with dyads, revealing diverse, highly structured approaches tailored to specific relational challenges. Whether it's a psycholytic (medium) dose to facilitate unarmored communication in Imago Relationship Therapy, a psychedelic (macro) dose to provide radical perspective shifts in Integrative Behavioral Couple Therapy, or even staggered dosing in Emotionally Focused Couple Therapy to choreograph vulnerability and receptivity, ketamine acts as a catalyst for deeply meaningful encounters. For some, the Internal Family Systems (IFS) approach even involves only one partner taking a psychedelic dose, creating a "Golden Hour" of pure, undefended self-expression that can trigger "contagious empathy" in the sober partner.Crucially, the medicine is not a magic cure. It's a temporary window of opportunity. The lasting work happens in the meticulous preparation—where couples map out their conflict cycles and set clear intentions—and the essential integration phase, where abstract insights are transformed into practical, daily habits. While the field is nascent and requires further rigorous research, these pioneering therapists are exploring how ketamine can foster radical vulnerability and help couples redefine relationship work, moving from relentless fighting to simply learning how to put the armor down and access the deep connection that's already there.Reference:Avruch, D. O. (2026). Approaches to ketamine-assisted couple therapy. Frontiers in Psychology, 17, Article 1843151. https://doi.org/10.3389/fpsyg.2026.1843151

Ketamine offers rapid relief from severe depression and suicidal ideation, but its effects are often fleeting, creating a "fade" that leaves patients vulnerable. This Stanford study, published in the *American Journal of Psychiatry* (2026), tackles this challenge by exploring a novel pharmacological strategy: using low-dose buprenorphine to extend ketamine's benefits. Researchers discovered that ketamine's magic might rely on the brain's mu-opioid receptor pathways, not just the glutamate system. Buprenorphine, a partial mu-opioid agonist, gently stimulates these pathways, acting like a "trellis" to support new neural connections formed by ketamine. This approach, tested on outpatients with severe depression and suicidal ideation, showed remarkable results. Patients receiving buprenorphine maintained a significant reduction in suicidal thoughts, while those on a placebo experienced a return of ideation. Intriguingly, buprenorphine specifically targeted suicidal ideation without significantly impacting overall depression. This suggests that these conditions may operate on distinct neurobiological circuits, challenging the conventional view that suicidal ideation is simply an extreme symptom of depression. This study provides a potentially scalable and safe therapeutic option, offering a new key to turn off the switch for patients in desperate need. Reference: Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., & Schatzberg, A. F. (2026). Low-dose buprenorphine following ketamine treatment for suicidal ideation in major depressive disorder: A randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry*, *XX*(XX), 1–11. https://doi.org/10.1176/appi.ajp.20250840

Ketamine therapy, a beacon of hope for treatment-resistant depression, has been gaining traction, but its off-label use has raised concerns about standardization and safety. Imagine a powerful dissociative anesthetic, originally intended for battlefield use, being administered in strip mall clinics without proper monitoring or trained psychiatric support! The risk? A destabilized patient leaving traumatized instead of healed. Enter the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3), armed with a rigorous, interdisciplinary approach using the Delphi method. This isn't your typical boardroom vote; it's an anonymous, iterative process designed to eliminate bias and ego, ensuring that guidelines reflect true expert consensus. With insights from psychiatrists, anesthesiologists, ER physicians, and psychotherapists, the new guidelines address crucial aspects like comprehensive patient evaluations, dose titration, and monitoring requirements. These guidelines aren't just about individual safety; they're a step toward standardizing the industry, paving the way for insurance coverage and broader access. But will these new rules squeeze out clinics prioritizing profit over patient well-being? And what does this mean for the future of other emerging mental health therapies waiting in the wings? Reference: Mathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., Ko, H. S., McShane, R., Prashad, S., Santini, T., Stewart, L. H., Sullivan, P., Wolfsohn, S. D., Robinson, J. O., McGuire, A. L., & McInnes, L. A. (2026). Interdisciplinary, delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). Journal of Affective Disorders, 121970. https://doi.org/10.1016/j.jad.2026.121970

This episode dives into a 2026 case report revealing a surprising drug interaction: ketamine, used for pain management, induced the liver to accelerate the breakdown of critical immunosuppressant medications in a heart transplant recipient. Transplant patients rely on a delicate balance, where drugs like tacrolimus and sirolimus prevent organ rejection. However, these drugs are metabolized by specific liver enzymes (CYP3A4), making them vulnerable to interactions. In this case, a patient receiving ketamine for post-surgical pain experienced a dramatic drop in immunosuppressant levels, placing his transplanted heart at risk. Doctors responded by drastically increasing the doses, but the drug concentrations barely budged. The ketamine was essentially "teaching" the liver to clear the drugs faster, a phenomenon known as enzyme induction. The peak effect occurred a week after ketamine was started, followed by a slow recovery over three weeks. The episode emphasizes the importance of vigilant monitoring when ketamine is used in patients on narrow therapeutic range medications, and that monitoring should continue for three weeks after ketamine is discontinued to catch any potential rebound effects. Reference: Stojanova, J., Murnion, B., Burrows, F., Carlos, L., Mizuno, T., Nadai, T., Helsby, N., Muthiah, K., & Day, R. (2026). Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *46*(e70150). https://doi.org/10.1002/phar.70150

For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer?We unpack the paradox of using a dissociative anesthetic to sharpen the mind. The secret lies in looking past the acute intoxication phase—the temporary "construction zone"—to the structural remodeling that follows. We explore ketamine's two-phase neuroprotective mechanism: acting first as a "fire extinguisher" to block NMDA receptors and stop toxic glutamate floods (excitotoxicity), and second as "fertilizer" by releasing BDNF to sprout new neural bridges (synaptogenesis).While animal models show a staggering 93.2% success rate in restoring cognitive functions like working memory and spatial learning, the review's single human study on Huntington's disease showed short-term cognitive impairment. We discuss why timing and context are everything: to truly harness this drug, the biological "window of neuroplasticity" must be actively paired with rigorous, targeted neurorehabilitation to guide the brain's rewiring.Reference:Leon-Rojas, J. E., Mascialino, G., Vinueza Mera, L., Hinojosa-Figueroa, M. S., Navas Arias, C. F., Cadena Barberis, E. D., & Sacks-Zimmerman, A. (2026). Ketamine as a potential cognitive enhancer in neurological disorders: Evidence from preclinical and clinical studies. Frontiers in Neurology, 17, 1786249. https://doi.org/10.3389/fneur.2026.1786249

In Episode 57, we explore a groundbreaking 2026 study out of Hungary by Koncz and colleagues that challenges the foundation of modern psychiatry: do you actually have to "trip" to heal? For years, the pharmaceutical industry has searched for a sanitized, at-home version of ketamine, hoping that R-ketamine (arketamine) could deliver neuroplasticity without the intense psychotomimetic effects of standard S-ketamine (esketamine).By utilizing quantitative EEG (qEEG) signals, researchers discovered the "Gamma-Delta Shift"—the electrical signature of the brain actively rewiring. S-ketamine acts like a controlled forest fire: it triggers a massive, high-frequency "gamma storm" (the trip) which creates a massive cellular energy debt. This debt forces a mandatory "delta rebound" during deep sleep, which is when the actual physical remodeling and synaptic plasticity occur.The shocking twist? Even at four times the normal dose, arketamine completely failed to trigger this shift. This perfectly mirrors its recent failure in human clinical trials, where it did not show a statistically significant antidepressant effect compared to a placebo. The data draws a clear line: you cannot bypass the chaotic exertion phase and still get the structural repair. The altered state isn't a side effect to be engineered away; it is a necessary feature of the cure.Reference:Koncz, S., Pothorszki, D., Papp, N., Pál, D., & Bagdy, G. (2026). Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon. British Journal of Pharmacology, 1-15. https://doi.org/10.1111/bph.70399

For decades, medicine has sold us the comforting "light switch" theory: under general anesthesia, we simply cease to exist for a few hours. But in Episode 54, we unpack Bruno Tonetto’s terrifying and fascinating 2026 paper, "Conscious Under Anesthesia," which argues that we have confused the silence of the body with the absence of the mind.We explore the "broken speaker" analogy, revealing how paralytics trap patients in a silent body, while premedications like Midazolam act as chemical memory wipers (anterograde amnesia) to ensure the experience is forgotten. The most chilling evidence? The Isolated Forearm Technique, where researchers block the paralytic from reaching one arm, revealing that up to a third of paralyzed, "unconscious" patients can squeeze a hand to answer complex questions—yet remember absolutely nothing upon waking.Finally, we tackle the "Ketamine Paradox." As an approved anesthetic that triggers hyper-vivid, mystical experiences, ketamine completely breaks the traditional "production model" of the brain. Instead, Tonetto argues for the "constraint model," suggesting the brain is not a turbine generating consciousness, but a "reducing valve" filtering it. When ketamine unplugs the sensory inputs, the filter breaks, and the mind expands.Reference:Tonetto, B. (2026). Conscious under anesthesia: What the clinical evidence actually shows. Project: Return to Consciousness. https://brunoton.github.io/return-to-consciousness/exports/pdf/cua.pdf

Clinicians measure success in symptom scores and receptor occupancy, but for patients with Treatment-Resistant Depression (TRD), success is defined by something far more personal: the return of connection, clarity, and "life." In this episode, we amplify the "Patient's Voice" through a comprehensive synthesis of qualitative studies by Walasek and colleagues.We trace the emotional arc of treatment, starting with the profound ambivalence of patients who see ketamine as a "last resort"—terrified it will be just another failure in a long line of disappointments. We then step inside the acute experience itself, often described as a "rollercoaster" where euphoria and panic can flip on a dime, making the safety of the setting and the empathy of the staff critical to preventing trauma.The discussion challenges the medical model's obsession with dissociation as a measurable "active ingredient," revealing that patients value the meaning they make of the experience—the moments of insight and emotional release—far more than the intensity of the "trip" itself. Finally, we expose the hidden barriers to care: the crushing financial burden, the stigma of using a "party drug," and the finding that patients often attribute up to 50% of their therapeutic outcome not to the molecule, but to the kindness and support of the clinical staff.Reference:Walaszek, M., Cubała, W. J., & Kachlik, Z. (2025). Patients’ voices on ketamine for treatment-resistant depression: A narrative review of qualitative perspectives. Journal of Clinical Medicine.

Sickle Cell Disease (SCD) pain crises are the leading cause of hospitalization for affected children, causing excruciating vaso-occlusive episodes where misshapen blood cells block oxygen flow to tissues. For decades, the standard treatment has been high-dose opioids, but this often leads to tolerance, inadequate relief, and the dangerous paradox of opioid-induced hyperalgesia—where the treatment actually makes the nervous system more sensitive to pain.In this episode, we analyze a massive cross-sectional study from 44 U.S. children’s hospitals involving over 74,000 admissions. The study asks a critical question: Can ketamine, an NMDA receptor antagonist that "turns down the volume" on central sensitization, break the cycle of pain where opioids fail?The findings reveal a slow but steady rise in ketamine use (doubling from 2.3% in 2016 to 5.7% in 2023), mostly reserved for older children with severe disease markers like chronic pain or hydroxyurea use. But the most stunning insight is about timing. The study found that when ketamine was administered early (within the first 3 days of admission), it cut the median hospital Length of Stay (LOS) in half—from 12 days to just 6 days—and drastically reduced the days patients needed IV opioids.Despite these compelling results, huge gaps in care remain, with some hospitals using ketamine in 20% of cases and others in 0%. We discuss the institutional barriers, stigma, and red tape that prevent clinicians from using this powerful tool when it matters most: early in the crisis.Reference:Jenkins, A. M., Hendry, E., Power-Hays, A., Valentino, M., Hall, M., Kyler, K. E., Antoon, J. W., Tang Girdwood, S., Goldman, J. L., Morel, A. N., Savage, T. J., Orth, L. E., & Archer, N. M. (2025). Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016826

urgery is a trauma that wrecks sleep, and for vulnerable patients, Post-Operative Sleep Disturbance (PSD) is a serious complication linked to delirium, increased pain, and slowed recovery. In this episode, we dive into a fascinating study that connects three seemingly unrelated dots: ketamine, sleep, and the oral microbiome.Researchers treated 130 high-risk surgical patients with a continuous low-dose infusion of esketamine. The clinical results were striking: the rate of PSD dropped from 65% in the control group to just 43% in the esketamine group. Patients reported significantly better sleep quality and required far fewer opioids like hydromorphone.But the real surprise was found in their saliva. The study revealed that esketamine treatment actively reshaped the oral microbial community—boosting beneficial bacteria like Streptococcus while suppressing groups like Bacteroidota that were linked to poor sleep. Why would an IV anesthetic change mouth bacteria?We explore the leading theories:Systemic Anti-Inflammation: Surgery floods the body with pro-inflammatory cytokines (a "systemic fire"). Ketamine’s powerful anti-inflammatory properties may calm this environment, making the host less hospitable to stress-related microbes.The Gut-Oral Axis: Ketamine may influence the gut microbiome, with effects rippling up to the mouth to stabilize the body's entire ecosystem.This research challenges us to rethink how psychiatric drugs work—not just by hitting receptors in the brain, but by restoring ecological balance to the nerves, immune system, and the trillions of microbes that live within us.Reference:Li, X.-Y., Qiu, D., Du, N., Hashimoto, K., Wang, X.-M., & Yang, J.-J. (2025). Esketamine prevents postoperative sleep disturbance in patients with preoperative sleep disorders: A role for oral microbiota. Translational Psychiatry, 15(1), 501. https://doi.org/10.1038/s41398-025-03705-9

Catatonia is often misunderstood as simple immobility, but it is a terrifying, life-threatening syndrome of stupor, mutism, and extreme negativism—a state where the brain is essentially "frozen." For decades, the standard protocol has been to step on the "brake pedal" using GABA-ergic drugs like lorazepam, followed by Electroconvulsive Therapy (ECT) if medication fails. But what happens when the brakes don't work, and ECT is medically unsafe or unavailable?This episode analyzes a new systematic review of 10 unique case reports that suggests NMDA receptor antagonists like ketamine and esketamine could be the "skeleton key" for these desperate scenarios. We explore the neurochemistry of switching from the failed inhibitory (GABA) pathway to directly targeting the excitatory (Glutamate) system. The theory? Refractory catatonia may be driven by a massive glutamate hypo-function—the brain's engine isn't firing—and ketamine triggers the necessary surge to reset the circuit.The clinical results discussed are striking: 100% of the patients in the review showed symptom improvement, often within hours to days. We also debunk the common fear that ketamine might destabilize these fragile patients by triggering mania or psychosis; the review found these risks were not supported by the data. Finally, we highlight the practical game-changer of intranasal esketamine, which allows clinicians to bypass the resistance often seen in mute, withdrawn patients who cannot swallow pills.Reference:van der Meer, P. B., Verboeket, S., Slooter, A. J. C., Schoones, J. W., van Noorden, M. S., Somers, M., Batalla, A., & Dols, A. (2025). Treatment with (es)ketamine in catatonia: A systematic review of case reports. The Journal of Clinical Psychiatry, 86(4), Article 25br15940. https://doi.org/10.4088/JCP.25br15940

Chronic mental illnesses like severe MDD (major depressive disorder) and PTSD are alarms, not just for the mind, but for the body. This episode explores the fact that ongoing trauma and depression accelerate biological aging, leading to reduced health span and higher risks for chronic diseases. But can rapid, effective psychiatric treatment actually reverse this damage?We dive into a compelling pilot study that gave a series of six sub-anesthetic ketamine infusions to 20 participants with treatment-resistant depression or PTSD. The researchers used second-generation epigenetic clocks to measure biological age—the actual cellular wear and tear, separate from chronological age. The most advanced clock used, OMICs-AGE, integrates DNA methylation with surrogates for over 40 proteins, metabolites, and clinical markers across eight physiological systems, showing the strongest link to mortality risk.The findings are potentially groundbreaking:Age Reversal: The study found a clear, statistically significant reduction in epigenetic age across several markers after treatment. Critically, the signal captured by OMICs-AGE held up under stringent statistical correction, suggesting a genuine biological age deceleration.The Mechanism: This reversal is linked to specific anti-aging pathways. Ketamine treatment led to a significant reduction in CD4 T memory cells, which are markers for systemic inflammation and aging (immunosenescence). Further analysis revealed shifts in metabolic and neuroimmune markers clustered around circadian sleep regulation and T-cell differentiation.While this was a small pilot study without a non-treatment control group , the robustness of the OMICs-AGE signal suggests a profound implication: the ultimate longevity treatment may lie not in anti-aging creams, but in aggressively treating the mental illness that accelerates the biological clock in the first place. Mental health truly is longevity health.Reference:Dawson, K. L., Carangan, A. M. J. M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B. C., Mendez, T. L., Smith, R. M., Dawson, M. S., Mallin, M. P., Higgins-Chen, A. T., & Dwaraka, V. B. (2025). Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study. Translational Psychiatry, 15(1), 452. https://doi.org/10.1038/s41398-025-03683-y

When traditional antidepressants fail older adults with treatment-resistant depression, where can they turn? Standard therapies, built on the monoamine hypothesis, often fall short in aging brains or those affected by neurodegenerative diseases like Alzheimer's, as the pathways they rely on may be dysfunctional.This episode dives deep into a systematic review exploring a paradigm-shifting alternative: ketamine and its derivatives, esketamine and arketamine. These compounds sidestep conventional mechanisms, instead targeting the NMDA receptor to promote widespread neuroplasticity. We uncover the powerful clinical findings, revealing that ketamine provides rapid, robust relief and is equally effective in geriatric and non-geriatric populations.Discover how ketamine not only improves mood but also restores vital executive functions, helping patients think more clearly. We'll explore the neurological data showing how the treatment restores the brain's crucial "excitation-inhibition" balance, leading to more organized cognitive processing. While the immediate benefits are profound, we also confront the critical unresolved question of long-term sustainability. Join us to understand how this research challenges us to move beyond targeting single chemicals and toward therapies that aim to rebuild the entire circuitry of the mind.ReferenceAltamura, M., Leccisotti, I., Moretti, M. C., Bellomo, A., Panza, F., Cassano, T., & Lozupone, M. (2025). Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence. Biomedicine & Pharmacotherapy, 188, 118199. https://doi.org/10.1016/j.biopha.2025.118199

Dive into the profound and complex world of ketamine therapy in this episode of the Talking Ketamine podcast, where we explore "The Paradox of Hope". We unpack a powerful qualitative study, "Lived Futures in Ketamine Therapy: A Qualitative Study of Hope and Temporality in Treatment Resistant Depression" , which gives us a raw, unfiltered look into the lives of individuals battling severe treatment-resistant depression.Discover the deep-seated hopelessness that years of failed treatments can create. You'll hear about the "therapeutic burden" that chips away at a person's spirit, leaving them with an "active, almost protective disbelief" in the possibility of recovery.Then, witness the shocking "temporal rupture" that ketamine's rapid effects create, forcing patients to reconcile a lifetime of futility with immediate, undeniable change. This episode explores how patients navigate the societal stigma of a drug often labeled a "party drug" and how the clinical setting provides a crucial sense of legitimacy and safety.Most importantly, we reveal how ketamine fosters a new, more resilient form of hope—one that is "grounded in real results" and tangible changes. This transformation allows patients to separate their identity from their illness , viewing it as a "brain problem" that can be fixed, rather than a personal failing.Join us as we explore how a medical innovation can fundamentally reshape what it means to heal, offering a truly "tangible, evidence-based possibility for everyone who needs it".APA Citation of Subject Study:Ninnemann, K. M. (2025). Lived futures in ketamine therapy: A qualitative study of hope and temporality in treatment-resistant depression [Doctoral dissertation, Case Western Reserve University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=case1749123703760677

Welcome to Talking Ketamine, Episode 26, where we're delving into a fascinating and often overlooked aspect of psychedelic research: the very tone of scientific conversation itself! You know that ketamine and psilocybin are generating immense buzz for their therapeutic potential, especially for tough conditions like treatment-resistant depression. But is the academic literature a unified voice of optimism? Not at all. It’s a complex tapestry woven with threads of cautious optimism and critical concern about abuse and risk.In this episode, we unpack groundbreaking research from a Master's thesis by Oksana Abramova, which employs cutting-edge AI to map these intricate narrative shifts. Using a fine-tuned SciBERT language model, specially trained on scientific texts, the AI meticulously predicts sentiment – the positive or negative leaning – even within the subtle, hedged language (think "suggests" instead of "proves") characteristic of academic writing. Complementing this, BERTopic identifies the dominant themes, revealing whether the focus is on therapeutic benefits or potential harms.The findings are truly insightful. You’ll discover how psilocybin research shows a clear trend of increasing positivity in recent years, mirroring its re-emergence as a therapeutic tool. But ketamine’s scientific narrative reveals a more stable sentiment trajectory. Why the difference? We explore how ketamine's longer, more controversial history – as an anesthetic and a substance with abuse potential – likely contributes to this consistent, balanced tone.Beyond overall trends, we reveal how sentiment can shift dramatically even within a single research paper, from hopeful abstracts to cautious discussion sections that thoroughly explore limitations. Perhaps most surprisingly, the AI analysis discovers a weak correlation between a paper's topic and its sentiment. This means an article focused on therapeutic use isn't necessarily overflowing with positivity; it might instead reflect a rigorous, critical examination of treatment claims. Conversely, a paper detailing risks could still carry an underlying hopeful tone, emphasizing the importance of understanding dangers to enable safe therapeutic application.This episode offers a unique lens, showing how AI helps us to look deeper than the headlines, appreciating the full, nuanced spectrum of scientific discourse. It's a powerful reminder that truly understanding research means grasping not just what is said, but how it's said, revealing the evolving perspectives and inherent caution of good science. Don't miss this opportunity to understand the hidden dynamics shaping the future of psychedelic medicine.Reference: ABRAMOVA, O. (2024). Analysing Valence Shifts in Scientific Narratives on Psychedelics using BERT and Topic Modeling. https://thesis.unipd.it/handle/20.500.12608/89824

Episode 7 of Talking Ketamine explores the groundbreaking potential of ketamine as a treatment for PTSD. This episode examines a recent study on how a single dose of ketamine, combined with trauma-focused therapy, affects individuals with chronic PTSD. Discover how ketamine may promote flexibility in brain pathways, potentially rewiring the brain's response to traumatic memories, and explore how these changes might feel for someone undergoing treatment. While highlighting that ketamine treatment for PTSD is still experimental, this offers a hopeful glimpse into the future of mental health treatment and the incredible ability of the brain to heal.The study in this episode:Duek, O., Korem, N., Li, Y., Kelmendi, B., Amen, S., Gordon, C., et al. (2023). Long term structural and functional neural changes following a single infusion of Ketamine in PTSD. Neuropsychopharmacology, 48(12), 2056–2066. https://doi.org/10.1038/s41386-023-01606-3